I knew I’d officially become a “longevity influencer” this month when a company called Generation Lab reached out to offer me the chance to write about—and even receive—their new rejuvenation treatment, an injectable combination of two existing drugs which they call 1 Generation.
When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform.
